Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients

This study has been completed.
CTI Clinical Trial and Consulting Services
Aptuit Inc.
Information provided by (Responsible Party):
Veloxis Pharmaceuticals Identifier:
First received: October 2, 2008
Last updated: July 3, 2012
Last verified: July 2012

The purpose of this study is to demonstrate the pharmacokinetics (PK, measuring the amount of medication in blood samples) and safety of a new medicine, LCP-Tacro™ tablets, and Prograf® capsules, a drug commonly taken by transplant recipients to prevent the body from rejecting a transplanted kidney. LCP-Tacro is a tablet containing the same active ingredient (tacrolimus) that is in Prograf capsules, but the tablet has been designed to release tacrolimus over an extended period so that it only has to be taken once daily. LCP-Tacro is an investigational drug.

This study will evaluate the levels of tacrolimus in the blood in the first two weeks after a kidney transplant in patients randomly assigned (by chance, like flipping a coin) to take either LCP-Tacro™ tablets (tacrolimus) once daily or Prograf® capsules twice daily. In addition, patients will remain on study drug for 360 days in order to evaluate the relative safety of LCP-Tacro™ tablets compared to Prograf over a longer period of time.

Condition Intervention Phase
Kidney Transplantation
Renal Transplantation
Drug: tacrolimus (Tacro™)
Drug: Prograf®
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label, Multi-Center, Randomized Trial To Demonstrate The Pharmacokinetics Of LCP-Tacro™ Tablets Once Daily and Prograf® Capsules Twice Daily In Adult De Novo Kidney Transplant Patients

Resource links provided by NLM:

Further study details as provided by Veloxis Pharmaceuticals:

Primary Outcome Measures:
  • Pharmacokinetics of LCP-Tacro™ tablets in the first 14 days after transplantation in adult de novo kidney recipients. [ Time Frame: 14 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Comparative pharmacokinetics. Efficacy death, graft loss, biopsy proven acute rejection) and safety of LCP-Tacro™ tablets and Prograf capsules within 360 days after kidney transplantation. [ Time Frame: 360 days ] [ Designated as safety issue: Yes ]

Enrollment: 63
Study Start Date: September 2008
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
LCP - Tacro™ tablets, once daily (LifeCycle Pharma A/S, Hørsholm DK)
Drug: tacrolimus (Tacro™)
LCP - Tacro™ tablets
Other Name: LCP - Tacro
Active Comparator: B
Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
Drug: Prograf®
Prograf® capsules, twice daily
Other Name: Prograf

Detailed Description:

This study was a randomized, parallel-group, open label, multicenter study in adult de novo kidney transplant patients to demonstrate the pharmacokinetics and safety of LCP-Tacro tablets and Prograf capsules in the first 2 weeks after kidney transplantation. In addition the study compared the efficacy and safety of LCP-Tacro and Prograf over an additional 50 weeks after kidney transplantation. Eligible patients were randomized (1:1 ratio) within 12 hours after transplantation (Day 0) to receive either: 1) LCP-Tacro tablets orally once daily (QD) in the morning, with an interval of 24+/- hours between doses, starting at 0.14 mg/kg (the starting daily dose for African-American patients was 0.17 mg/kg), or 2) Prograf capsules in 2 equally divided doses for African-American patients was (0.2 mg/kg total daily dose) as recommended in the U.S. Prescribing Information (Astellas Pharma US, April 2006). Day 1 was defined as the day on which the first morning dose of study medication was given which was to be within 48 hours of transplantation. Subsequent doses of study medication were adjusted to maintain target whole blood tacrolimus trough level of 7 to 20 ng/mL for the remainder of the pharmacokinetic phase of the study (Day1 through Day 14). Twenty-four-hour pharmacokinetic assessments were performed on Days 1, 7, and 14. Following completion of the third and final pharmacokinetic assessment on the morning of Day 14, patients entered the maintenance phase (Days 15 to 360) of the study and remained on their assigned study medication until Day 360. Visits for safety assessments and tacrolimus trough levels during the maintenance phase were on Days 42, 90, 120, 180, 270, and 360. On Day 360, the patients were placed on a maintenance immunosuppressive regimen determined by their treating physician.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult men and women at least 18 years of age who are recipients of a kidney transplant from a deceased donor or a live donor and who receive their first oral dose of randomized study drug within 48 hours of the transplant surgery (graft reperfusion)

Exclusion Criteria:

  • Recipient of any transplanted organ other than a kidney
  • Recipients of a kidney from a non-heart beating donor
  • Recipients of a kidney from an ABO incompatible donor
  • Recipients of a kidney with a cold ischemia time of ≥ 36 hours
  • Recipients of a bone marrow or stem cell transplant
  • Patients with a white blood cell count ≤ 2.8 x 109/L unless the absolute neutrophil count (ANC) is > 1.0 x 109/L
  • Patients with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) enzyme levels > 3 times the upper limit of normal during the 30 days prior to the transplant procedure
  • Patients who fail a drugs of abuse screen
  • Patients unable to swallow study medication
  • Patients incapable of understanding the purposes and risks of the study, who cannot give written informed consent, or who are unwilling to comply with the study protocol
  • Pregnant or nursing women (women of childbearing potential must have a negative serum pregnancy test within seven days prior to receiving study medication)
  • Patients with reproductive potential who are unwilling/unable to use a double barrier method of contraception throughout the duration of the study
  • Patients who were treated with any other investigational agent in the 30 days prior to enrollment
  • Patients who are hepatitis C virus (HCV) negative who have received a HCV positive (HCV RNA by polymerase chain reaction (PCR) or HCV antibody) donor kidney
  • Patients seropositive for human immunodeficiency virus (HIV)
  • Patients with a current malignancy or a history of malignancy (within the past 5 years), except basal or non-metastatic squamous cell carcinoma of the skin that has been treated successfully
  • Patients with uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives
  • Patients with severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus
  • Patients with a known hypersensitivity to tacrolimus
  • Patients with any form of current substance abuse, psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00765661

United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267
Sponsors and Collaborators
Veloxis Pharmaceuticals
CTI Clinical Trial and Consulting Services
Aptuit Inc.
Principal Investigator: Rita Alloway, PharmD University of Cincinnati,
  More Information

No publications provided

Responsible Party: Veloxis Pharmaceuticals Identifier: NCT00765661     History of Changes
Other Study ID Numbers: LCP - Tacro 2017
Study First Received: October 2, 2008
Last Updated: July 3, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Veloxis Pharmaceuticals:

Additional relevant MeSH terms:
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on November 20, 2014